Piot, P; Caldwell, A; Lamptey, P; Nyirenda, M; Mehra, S; Cahill, K; Aerts, A (2016) Addressing the growing burden of non-communicable disease by leveraging lessons from infectious disease management. Journal of global health, 6 (1). 010304. ISSN 2047-2978 DOI: https://doi.org/10.7189/jogh.06.010304

Downloaded from: http://researchonline.lshtm.ac.uk/2537479/

DOI: 10.7189/jogh.06.010304

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
In recent decades, low-and middle-income countries (LMICs) have achieved decreased morbidity and mortality associated with infectious diseases and poor maternal-and child-health (MCH). However, despite these advances, LMICs now face an additional burden with the inexorable rise of non-communicable diseases (NCDs). Deaths due to NCDs in LMICs are expected to increase from 30.8 million in 2015 to 41.8 million by 2030 [1]. While improvements in life expectancy, lifestyle and urbanisation go some way to explaining why more people in LMICs are affected by NCDs, it is less clear why these populations are contracting NCDs at a younger age and with worse outcomes than in high-income countries (HICs) [2].

Despite having a lower cardiovascular disease risk factor burden, LMIC populations have a four-fold higher mortality rate from cardiovascular events than HIC populations [3] in part due to a lack of access to quality, integrated health services and the poor availability of early interventions and effective NCD prevention programmes. The HIV/AIDS epidemic was the last time the world confronted a global health challenge that so disproportionately caused premature adult deaths in LMICs.

The conclusion is unavoidable: the time to act is now. Prevention of NCDs at a population and an individual level is key and requires policy and structural changes. We have a unique opportunity to learn from the successes of infectious disease control programmes in LMICs and leverage these to address the growing NCD burden. Translatable learnings include: 1) emphasizing primary prevention, particularly in those at highest risk; 2) targeting service delivery to high-risk populations; 3) enabling access to adequate, affordable care at community level; 4) engendering patient empowerment and involving people affected by chronic conditions; 5) enabling access to quality drugs and adherence programmes; 6) regularly measuring the effectiveness and impact of programmes to ensure their appropriateness and improvement; and 7) creating an environment of health financing for universal coverage.

Innovations to counter the emerging NCD epidemic must encompass both prevention and the delivery of...
Infectious disease programmes have used task-shifting, where less skilled health workers and community members are involved in delivery of health services. In India, we have seen this used for NCDs in the Arogya Kiran model where the existing health workforce was overstretched. Volunteers and teachers successfully delivered diabetes and hypertension screening and management to over 600,000 people [4]. Patient empowerment, and community involvement in health care delivery and governance, will be critical in tackling NCDs, since most are chronic conditions, which initially present silently and require long-term management [5].

In Malawi, recognizing the close relationship of HIV infection and cardiovascular diseases has led to screening for hypertension being integrated into HIV care [6]. In Ghana, decentralised community-based hypertension care, using digital technology, is helping to empower patients to manage their own disease: a model that is again adapted from HIV management [7]. We are also starting to see examples in India of MCH care coupled with life-long NCD screening and awareness programmes [8].

While these examples of managing the dual burden of infectious diseases and NCDs are encouraging, more needs to be done. The largest gap is in NCD prevention. Tackling the obesity epidemic and wrestling with the issues around curbing tobacco sales and smoking are rightly high on the NCD prevention agenda. The greatest opportunity is preventing a tobacco-related epidemic in sub-Saharan Africa where smoking levels are still low. Health budgets and development assistance for health must allocate resources commensurate with the dual disease burden. Health spending of governments in LMICs has tripled over the past 20 years, but remains low [9]. In addition, more health care models should consider diversified revenue streams or hybrid financing (eg, tiered payment schemes) to ensure sustainability. If equity is to be improved, patients need access to quality health care, through sustainable health-financing systems for universal health coverage, while reducing out-of-pocket expenditure for the under-served population.

Implementing such models will require strong government leadership and interventions, and partnerships across the public and private sectors. Some public–private partnerships (PPPs) in infectious diseases have demonstrated their potential to catalyze the delivery of, and access to, prevention and care through providing complementary strengths [10]. The private sector draws on its business and scientific expertise, focusing on strong results-based operations, whereas the public sector brings a wealth of expertise in implementation with equity, management and documentation.

The end-users of the services, including patients and health care providers, also need to be included from the outset to ensure that the models are people-centered, co-created, adapted to prevailing contextual nuances, and sustainable. If we build on what we have learnt from infectious disease management, we could have a transformational impact on the growing NCD burden.

We have a unique opportunity to learn from the successes of infectious disease control programmes and leverage these to address the growing non-communicable disease burden: 1) emphasizing primary prevention; 2) targeting service delivery to high-risk populations; 3) enabling access to adequate, affordable care; 4) engendering patient empowerment; 5) enabling access to quality drugs and adherence programmes; 6) regularly measuring the effectiveness and impact of; and 7) creating an environment of health financing for universal coverage.
**Funding:** The Novartis Foundation, a philanthropic organisation, provided external agency support (services provided by 90TEN Healthcare) for literature searches and for the preparation of an outline of the paper.

**Authorship declaration:** The opinion expressed in this article was developed following a Novartis Foundation workshop held in December 2014—the first in a series of Basel Dialogues on global health issues. The expert faculty discussed lessons learned and experience gained in managing infectious diseases and how these might inform future strategies on the emerging dual burden of disease (infectious and non-communicable) in low- and middle-income countries. All authors contributed equally to the article. The work to develop the article content was that of the contributing authors.

**Competing interests:** All authors have completed the Unified Competing Interest form at www.icmje.org/coiDisclosure.pdf (available on request from the corresponding author). We declare no competing interests. The Novartis Foundation provided no funding support to the non-Novartis Foundation authors for the preparation of the article and did not influence the content of the article. Two of the authors Dr. Ann Aerts, Head Novartis Foundation, and Aya Caldwell, Head Innovative Healthcare Delivery Solutions, are employed by the Novartis Foundation. Peter Piot has received grants from Gates Foundation, IMI, DFID and UNAIDS outside the submitted work and is a Board member for the Novartis Foundation. Peter Lamptey receives support from the Novartis Foundation for the Community based control of Hypertension Improvement Project (Com-HIP) and is the Principal Investigator for the evaluation of the programme. Kathy Cahill is Vice President International Development at PATH, which received a grant from the Novartis Foundation for a project in Vietnam focused on prevention of CVD.

**REFERENCES**

1 World Health Organization. Projections of mortality and causes of death, 2015 and 2030. Available: http://www.who.int/healthinfo/global_burden_disease/projections/en/. Accessed: 1 July 2015.

2 Alwan A, MacLean DR. A review of non-communicable disease in low- and middle-income countries. Int Health. 2009;1:3-9. Medline:24036289 doi:10.1016/j.inhe.2009.02.003

3 Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular risk and events in low-, middle- and high-income countries. N Engl J Med. 2014;371:818-27. Medline:25162888

4 Sogarwal R, Mehra R. Arroya Kiran model for early detection of diabetes and hypertension: an initiative for the community and by the community in India. BMC Health Serv Res. 2014;14 Suppl 2:113. Medline:24602215 doi:10.1186/1472-6963-14-S2-P113

5 The Economist Intelligence Unit. Sub-Saharan African healthcare: the user experience. A focus on non-communicable diseases. 2014. Available: http://www.economistinsights.com/sites/default/files/NCD%20Africa%20report.pdf. Accessed: 1 July 2015.

6 Muronya W, Sanga E, Talama G, Kumwenda JJ, van Oosterhout JJ. Cardiovascular risk factors in adult Malawians on long-term antiretroviral therapy. Trans R Soc Trop Med Hyg. 2011;105:644-9. Medline:21924753 doi:10.1016/j.trstmh.2011.07.016

7 FHI 360. Community-based Hypertension Improvement Project (ComHIP). Available: http://www.fhi360.org/projects/community-based-hypertension-improvement-project-comhip. Accessed: 1 October 2015.

8 MAMTA Health Institute for Mother and Child Health. Community engagement and health systems. Available: hhttp://mamta-himc.org/ncd/. Accessed: October 2015.

9 Institute for Health Metrics and Evaluation. Financing global health 2013: transition in an age of austerity. Seattle: IHME, 2014.

10 Dholakia YN. TB/HIV coordination through public private partnership: lessons from the field. Indian J Tuberc. 2013;60:23-7. Medline:23540085

**Correspondence to:**

Aya Caldwell
Novartis Foundation
Novartis Campus
Forum 1-3.92
4002 Basel
Switzerland
aya.caldwell@novartis.com